• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BDRX

    Biodexa Pharmaceuticals plc American Depositary Shs

    Subscribe to $BDRX
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for Biodexa Pharmaceuticals plc American Depositary Shs

    DatePrice TargetRatingAnalyst
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    See more ratings

    Biodexa Pharmaceuticals plc American Depositary Shs SEC Filings

    See more
    • SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/4/25 8:30:26 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/2/25 5:24:24 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      6/2/25 5:23:46 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      5/30/25 4:05:42 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      5/30/25 8:30:14 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      5/23/25 4:05:17 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      5/23/25 4:00:37 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      5/23/25 4:00:37 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      5/23/25 4:00:36 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      5/22/25 4:54:01 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Biodexa Pharmaceuticals plc American Depositary Shs Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/20/24 11:56:39 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/14/24 5:12:47 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/12/24 4:30:48 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/7/24 4:51:27 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      8/8/24 4:24:30 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      7/23/24 3:09:44 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Biodexa Pharmaceuticals plc American Depositary Shs Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

      June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes ("T1D"). The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and

      6/4/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shareholder Update

      May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced a brief update for shareholders. Financial positionAs of May 29, 2025, the Company had access to the following cash resources:   $ millionsCash at bank 5.7Cash in escrow for eRapa Phase 3 program 4.4  10.1   Undrawn CPRIT grant for eRapa Phase 3 program 11.9   Debt 0.5 The CPRIT grant, together with Company match means the eRapa Phase 3 program is substantially funded. Based on its latest projections,

      5/30/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Notice of General Meeting

      May 22, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Notice of General Meeting Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 11 June 2025 at 1.00pm was posted to shareholders today. The Board of Directors is proposing four resolutions: Ordinary Resolutions       1.   That, subject to and conditional on the passing of Resolution 4, each of the issued ordinary shares of £0.001 each in the capital of the Comp

      5/22/25 4:30:00 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

      May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced its collaboration partner, Rapamycin Holdings, Inc. d/b/a Emtora Biosciences ("Emtora") has been awarded an additional grant of $3.0 million from the Cancer Prevention & Research Institute of Texas ("CPRIT"). This award brings the total grant awarded by CPRIT t

      5/22/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

      May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 study targeted at an addressable market of $7.3Bn Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the European Commission (EC) has granted Orphan Drug Designation for eRapa in familial adenomatous polyposis (FAP), a largely inherited precancerous disea

      5/12/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Result of General Meeting

      May 2, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Result of General Meeting Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces that at its General Meeting held at 1.00pm BST today, ordinary resolutions 1 and 2 were passed by majorities of 62% and 61%, respectively. Special resolution 3 failed to pass with a majority vote of 71%. Because resolution 1 was contingent on the passing of resolution 3, resolution 1 also failed to pass. Commenting, Dr. Stephen Parker, Chairman of Biodexa said "It is unfortunate that resolution 3 faile

      5/2/25 4:30:00 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notice of General Meeting

      April 17, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Notice of General Meeting Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 2 May 2025 at 13:00 BST was posted to shareholders yesterday. The Board of Directors is proposing three resolutions: Ordinary Resolutions1.   That, subject to and conditional on the passing of Resolution 3, each of the issued ordinary shares of £0.00005 each in the capital of the Co

      4/17/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Preliminary Results for the Year Ended 31 December 2024

      April 11, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces its audited preliminary results for the year ended 31 December 2024. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is a clinical stage biopharmaceutical c

      4/11/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

      March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million Company match Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the results of its Type C meeting with the U.S. Food and Drug Administration ("FDA") regarding the protocol for the planned registrational Phase 3 study of eRapa in familial ad

      3/10/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

      March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the appointment of Precision for Medicine, LLC ("Precision") as the clinical research organization ("CRO") to conduct the European component of the upcoming registrational Phase 3

      3/6/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Biodexa Pharmaceuticals plc American Depositary Shs Financials

    Live finance-specific insights

    See more
    • Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

      CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. Biodexa's strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications. When Biodexa sees potential, it acquires these products from third parties under licensing agreements which generally call

      11/21/24 7:35:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Biodexa Pharmaceuticals plc American Depositary Shs Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Biodexa Pharmaceuticals PLC with a new price target

      Ladenburg Thalmann initiated coverage of Biodexa Pharmaceuticals PLC with a rating of Buy and set a new price target of $8.00

      2/8/24 7:21:49 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Biodexa Pharmaceuticals plc American Depositary Shs Leadership Updates

    Live Leadership Updates

    See more
    • Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

      March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the appointment of Precision for Medicine, LLC ("Precision") as the clinical research organization ("CRO") to conduct the European component of the upcoming registrational Phase 3

      3/6/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • Biodexa Appoints Ann Merchant to the Board of Directors

      Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, is pleased to announce the appointment of Ann Merchant to the Board of Directors of the Company as Non-executive Director with effect from 31 December 2023. Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and Externa

      12/29/23 4:05:00 AM ET
      $ALVO
      $BDRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations